k63

ICCB-19 hydrochloride (ICCB-19 HCl) is an inhibitor of TRADD (TNFRSF1A Associated Via Death Domain). It binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N), which interacts with the C-terminal domain (TRADD-C) and TRAF2 to modulate the ubiquitination of RIPK1 and beclin 1.

STK630921 is a blocker of IL-17A binding to the IL-17A receptor (IL-17RA).

CK-636 (CK-0944636), an Arp2/3 complex inhibitor, can inhibit actin polymerization induced by the human (IC50: 4 μM), fission yeast (IC50: 24 μM) and bovine (IC50: 32 μM) Arp2/3 complex, respectively.

TAK-632, a potent pan-Raf inhibitor (GenScript, 2020), is characterized by its molecular weight [M] for [C 22 H 19 FN 2 O 2] of 362.4 by LC-MS, with a purity of 99% (HPLC). The compound exhibits white to off-white solid form and has a melting point [M] ranging from 178°C to 182°C (GenScript, 2020). Its solubility profile includes DMSO, in which it is soluble to 100mM (GenScript, 2020).

MK-6325 is a potent inhibitor of the HCV NS3/4A protease.

TAK-637 is a tachykinin 1 (NK1) receptor antagonist.

Teduglutide (ALX-0600) is a glucagon-like peptide-2 analog that increases intestinal absorption by promoting mucosal growth and reducing mucosal degradation, improving intestinal recovery. It is used in the study of short bowel syndrome (SBS). Teduglutide activates NR4a1/nur77 expression and FXR signaling, alleviating intestinal dysfunction in mice and improving lung injury, making it useful for studying metabolic and cardiovascular diseases.

Indinavir sulfate (L735524 sulfate) is a HIV protease inhibitor.It inhibits the HIV-1 protease with an IC50 value of 0.41 nM and Ki value of 0.24 nM.

Indinavir is an orally administered, specific HIV protease inhibitor commonly used in combination therapy as part of highly active antiretroviral therapy (HAART) for HIV/AIDS. Indinavir also inhibits the activation of MMP-2 in endothelial cells and exhibits affinity for α7-nAchR and SARS-CoV-2 Mpro.

B 4148 is a bradykinin inhibitor.

ML323 is a reversible and effective USP1-UAF1 inhibitor in a Ub-Rho assay (IC50: 76 nM) and in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) (IC50: 174 nM 820 nM)and monoubiquitinated PCNA (Ub-PCNA) (IC50: 820 nM) as substrates, respectively.

cGMP-HTL, an autophagy-targeting chimera (AUTAC), consists of a HT-ligand, a linker, and a Cys-S-cGMP (autophagy tag), designed to enhance K63-linked ubiquitination of mitochondria. This novel clearance strategy features a degradation tag (guanine derivatives) and a specific warhead, facilitating targeted degradation [1].

FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2 serves as a linker for AUTAC4, a compound comprising a p-fluorobenzylguanine (FBnG) unit and a phenylindole moiety, capable of inducing K63-linked polyubiquitination and subsequent degradation of mitochondria within HeLa cells [1].

Cys-C-cGMP serves as an autophagy tag for AUTACs (autophagy-targeting chimeras). It enhances K63-linked ubiquitination of mitochondria within HeLa cells [1].

Anti-Polyubiquitin Antibody represents a highly specialized monoclonal antibody specifically engineered to target the complex lysine-linked polyubiquitin chains such as the K48 or K63 branched structures with exceptional binding affinity and selectivity, effectively facilitating the measurable detection and quantification of polyubiquitinated substrates across various preclinical experimental models to evaluate the dynamic regulation of the ubiquitin-proteasome system during strictly monitored laboratory observation periods.